Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Immunomedics Inc reports results from three phase I trials with IMMU-130 in Metastatic Colorectal Cancer


Monday, 7 Apr 2014 11:01am EDT 

Immunomedics Inc:Results from 3 Phase I trials with IMMU-130, the Company's investigational anti-CEACAM5 antibody conjugated to irinotecan-metabolite, SN-38.Antibody-drug conjugate (ADC) was therapeutically active in all 3 trials, but more frequent dosing schedule, with administrations of IMMU-130 once or twice-weekly for 2 weeks followed by week off.Says ADC was more active in patients with metastatic colorectal cancer (mCRC) than when administered every other week.Patients with advanced mCRC who relapsed after at least one irinotecan-containing treatment were enrolled in these multicenter trials.Patients completed at least 1 cycle of once-weekly therapy in this ongoing trial, with 3 out of 4 patients with computer tomography (CT) assessment reporting stable disease as their best response.For twice-weekly dosing regimen, 16 patients have been enrolled, with 8 patients having CT-assessments of response.Best responses out of 8 assessable patients included one having a partial response (shrinkage of 66 pct of target tumors measured by CT, based on RECIST criteria) and 5 patients having stable disease.Patient with partial response received 40 IMMU-130 injections over 8 months, with disease shrinkage first observed within 2 months from the start of treatment, and with partial response continuing for more than 4 months. 

Company Quote

3.43
0.06 +1.78%
22 Jul 2014